CompletedNot Applicable

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

United States100 participantsStarted 2014-06

Plain-language summary

Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.

Who can participate

Age range15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Any heart transplant recipient eligible for initiation and participation in the Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.
✓. Patients can be enrolled any time as long as they have not had more than 1 prior AlloMap.

What they're measuring

Clinical Outcomes (Vital Status of Heart Transplant Recipients)

Timeframe: 3 years

Trial details

NCT IDNCT02178943

SponsorCareDx

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-12

View on ClinicalTrials.gov More Cardiac Transplant Failure trials